2nd AnnualInvitation Only
CLL & Lymphoma
EUFocus Meeting 2027
Two days, 52 people, one room.
April 9 to 10, 2027
Seville, Spain
Dates
April 9-10, 2027
Two-day program
Venue
Seville, Spain
Hotel TBD
Audience
52 by invitation
26 KOLs & 26 fellows
Format
8 sessions · 24 talks
Expert talks + panels
A Curated Room: The People Shaping Practice
This second annual, invitation-only meeting convenes a deliberately small faculty: 26 leading CLL and lymphoma KOLs alongside 26 hand-selected fellows and junior faculty, the clinicians defining today’s standards and the ones who will define the next decade’s, in one room for two days.
The science tracks where treatment is moving: fixed duration and continuous frontline strategies in CLL, MRD-guided decisions, CAR-T engineering and bispecific bridging, and the reshaped relapsed setting in Hodgkin lymphoma. Every session pairs expert talks with a moderated panel, sustained, close-quarters engagement rather than a lecture hall.
BTKi & BCL2i CombinationsMRD-Guided TreatmentRichter TransformationCAR-T & BispecificsBTK DegradersCLL · LBCL · Hodgkin
Meeting Co-Chairs
Franck Morschhauser
CHU de Lille, Lille, France
Stephan Stilgenbauer
Ulm University Hospital, Ulm, Germany
Faculty Drawn From
Lille · Cologne · Institut Curie · Vall d’Hebron · Amsterdam UMC · Oxford · Ulm and other leading European cancer centers
52
Invited attendees only, sustained access, not a crowd
1:1
KOLs to rising faculty, a hand-picked balance in every session
14
Established US Focus Meetings behind it, a proven platform, not a one-off
CLL & Lymphoma EU Focus Meeting 2027
Faculty
Listed alphabetically by surname
Inhye Ahn
Dana-Farber Cancer Institute, Boston, MA
Marion Alcantara
Institut Curie, Paris, France
Peter Borchmann
University Hospital Cologne, Köln, Germany
Francesc Bosch
Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Paul Bröckelmann
University Hospital Cologne, Köln, Germany
Vincent Camus
Centre Henri Becquerel, Rouen, France
Björn Chapuy
Charité, Berlin, Germany
Alexis Claudel
CHU Mondor / Institut Mondor de Recherche Biomédicale (IMRB), Créteil, France
Kirsten Fischer
University Hospital Cologne, Köln, Germany
Arnon Kater
Amsterdam UMC, Amsterdam, Netherlands
Franck Morschhauser
CHU de Lille, Lille, France
Edurne Mugarza Strobl
Francis Crick Institute, London, UK
Talha Munir
Leeds Teaching Hospitals, Leeds, UK
Carsten Niemann
University of Copenhagen, Copenhagen, Denmark
Sergio Roa
Universidad de Navarra (CIMA), Pamplona, Spain
Cedric Rossi
CHU Dijon, Dijon, France
Davide Rossi
Institute of Oncology Research (IOR), Bellinzona, Switzerland
Clémentine Sarkozy
Institut Curie, Saint-Cloud, France
Lydia Scarfò
IRCCS Ospedale San Raffaele, Milan, Italy
Anna Schuh
University of Oxford, Oxford, UK
Stephan Stilgenbauer
Ulm University Hospital, Ulm, Germany
Eugen Tausch
Ulm University Hospital, Ulm, Germany
Alessandra Tedeschi
Niguarda Hospital, Milan, Italy
Benoit Tessoulin
Nantes University Hospital, Nantes, France
Bastian von Tresckow
University Hospital Essen, Essen, Germany
Clemens Wendtner
Munich, Germany
Two Days, Eight Sessions
Agenda
Presentations15 min
Panel Discussions30 min
Lunch50 min
Day One · Friday, April 9, 2027
Session IBiological Insights and Diagnostic Tests to Guide Management
Moderator
Early Stage CLL – How to Diagnose and Manage
Anna SchuhUniversity of Oxford, Oxford, UK
Prognostic and Predictive Markers in the Treatment Context
Eugen TauschUlm University Hospital, Ulm, Germany
Accelerated CLL and Richter Transformation – How to Diagnose and How to Treat?
Davide RossiInstitute of Oncology Research (IOR), Bellinzona, Switzerland
Panel Discussion
Session IIThe Great Debate: What Is the Optimal Front-Line Treatment for Specific Disease / Patient Profiles?
Moderator
Continuous BTKi +/- CD20 Antibody
Alessandra TedeschiNiguarda Hospital, Milan, Italy
Fixed Duration CD20 Antibody + BCL2i
Kirsten FischerUniversity Hospital Cologne, Köln, Germany
Fixed Duration BTKi + BCL2i
Carsten NiemannUniversity of Copenhagen, Copenhagen, Denmark
Panel Discussion
Session IIITreatment Challenges and Complications
Moderator
Second Line Treatment Depending on Type of Prior Therapy and Response
Francesc BoschVall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Double-Exposed and Double-Refractory CLL
Inhye AhnDana-Farber Cancer Institute, Boston, MA
Infections – Prophylaxis and Treatment
Clemens WendtnerMunich, Germany
Panel Discussion & Take-Home Points From Day 1
Session IVExperimental Approaches: What Is the Next Therapeutic Revolution?
Moderator
MRD-Guided Treatment
Talha MunirLeeds Teaching Hospitals, Leeds, UK
BTK Degraders and Other Small Molecules
Lydia ScarfòIRCCS Ospedale San Raffaele, Milan, Italy
Immunotherapy With CARs, Bispecifics, etc.
Arnon KaterAmsterdam UMC, Amsterdam, Netherlands
Panel Discussion & Take-Home Points From Day 1
Day Two · Saturday, April 10, 2027
Session VNear Future Treatment of Large B-Cell Lymphoma
Moderator
Key Components of Chemo-Free Combinations as Frontline Therapy for Elderly / Frail Patients
Benoit TessoulinNantes University Hospital, Nantes, France
Bispecific Antibodies as Part of Bridging Before CAR-T: Pros and Cons
Bastian von TresckowUniversity Hospital Essen, Essen, Germany
High-Grade B-Cell Lymphoma: Clinically Relevant Sub-Entities and Innovative Therapeutic Approaches
Björn ChapuyCharité, Berlin, Germany
Panel Discussion
Session VICAR-T: Best Practice and Future Trends
Moderator
In Vivo CAR-T: Most Promising Engineering Technologies and Preliminary Clinical Results
Marion AlcantaraInstitut Curie, Paris, France
Radiotherapy Pre- and Post-CAR-T: Current Knowledge
Vincent CamusCentre Henri Becquerel, Rouen, France
Does Time-of-Day Infusion Impact Safety and Efficacy of CD19-Directed CAR T-Cell Therapy?
Edurne Mugarza StroblFrancis Crick Institute, London, UK
Panel Discussion
Session VIIHodgkin Lymphoma: Reshaping the Relapse / Refractory Treatment Landscape
Moderator
Which 2L Strategy After Failing Nivo-AVD
Paul BröckelmannUniversity Hospital Cologne, Köln, Germany
Which 2L Strategy After Failing BV-AVD / BrECADD Frontline Regimen
Peter BorchmannUniversity Hospital Cologne, Köln, Germany
Rethinking Registration Strategies for New Agents: The Example of PRMT5 Inhibitors
Cedric RossiCHU Dijon, Dijon, France
Panel Discussion & Take-Home Points From Day 2
Session VIIINew Biomarkers in NHL
Moderator
Deep Learning-Enabled Prognostic Stratification of Follicular Lymphoma From H&E Whole-Slide Images
Clémentine SarkozyInstitut Curie, Saint-Cloud, France
Patient-Derived Lymphoma Spheroids (PDLS) and Mouse Models to Study Immunotherapy Combinations for NHL
Sergio RoaUniversidad de Navarra (CIMA), Pamplona, Spain
ctDNA: What Information Needs to Be in a Translational ctDNA Paper to Make It Reliable?
Alexis ClaudelCHU Mondor / Institut Mondor de Recherche Biomédicale (IMRB), Créteil, France
Panel Discussion & Take-Home Points From Day 2
Partnership Opportunities Now Open
Bespoke engagement packages for a closed, invitation-only audience
Request the Prospectus →
Your Point of Contact
Killian Wyness
Account Executive, MD Education
killian.wyness@md-education.com